Search

Displaying results 8721 - 8730 of 10000 in total
  1. Drug

    Astegolimab

    go.drugbank.com/drugs/DB16386
    Investigational

    Astegolimab is under investigation in clinical trial NCT04386616 (A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia).

  2. Drug

    Dalantercept

    go.drugbank.com/drugs/DB14988
    Investigational

    Dalantercept is under investigation in clinical trial NCT00996957 (Study of ACE-041 in Patients With Advanced Solid Tumors or Relapsed/Refractory Multiple Myeloma).

  3. Drug

    Dotinurad

    go.drugbank.com/drugs/DB16145
    Investigational

    Dotinurad is under investigation in clinical trial NCT03372200 (Febuxostat-controlled, Double-blind, Comparative Study of FYU-981 in Hyperuricemia With or Without Gout).

  4. Drug

    Gotistobart

    go.drugbank.com/drugs/DB19100
    Investigational

    Gotistobart is under investigation in clinical trial NCT05671510 (ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors).

  5. Drug

    Namilumab

    go.drugbank.com/drugs/DB13037
    Investigational

    Namilumab has been used in trials studying the treatment of Plaque Psoriasis and Rheumatoid Arthritis.

  6. Drug

    Icrucumab

    go.drugbank.com/drugs/DB14824
    Investigational

    Icrucumab is under investigation in clinical trial NCT01111604 (A Study of IMC-1121B or IMC-18F1 in Colorectal Cancer).

  7. Drug

    GlycoPEG-GCSF

    go.drugbank.com/drugs/DB06022
    Experimental

    GlycoPEG-GCSF is a long-acting GlycoPEGylated granulocyte colony stimulating factor for the treatment of chemotherapy-induced neutropenia.

  8. Drug

    Bectumomab

    go.drugbank.com/drugs/DB04962
    Experimental

    Bectumomab (marketed under the trade name LymphoScan®) is a mouse monoclonal antibody and which it's used to treat non-Hodgkin's lymphoma. It has a radioisotope, technetium (99m TC) which it's added.

  9. Drug

    IDM-2

    go.drugbank.com/drugs/DB05293
    Experimental

    IDM-2 is composed of Monocyte-derived Activated Killer (MAK) cells. … IDM produces MAK cells from the patient's own white blood cells by activating these cells ex vivo to allow them to recognize and destroy tumor cells.

  10. Drug

    Prostaglandin G2

    go.drugbank.com/drugs/DB03866
    Experimental

    A cyclic endoperoxide intermediate produced by the action of CYCLOOXYGENASE on ARACHIDONIC ACID. It is further converted by a series of specific enzymes to the series 2 prostaglandins. [PubChem]